Reports
Sale
Global Genomics Market Size, Share, Growth, Trends, Analysis: By Deliverables: Product, Software and Services; By Technology: Sequencing, Microarray, Polymerase Chain Reaction (PCR), Nucleic Acid Extraction, Purification, Others; By Process; By Application; By End Users: Regional Analysis; Supplier Landscape; 2024-2032
Global Genomics Market Outlook
The global genomics market size was valued at USD 38.1 billion in 2023, driven by increased funding for genomic projects and the prevalence of chronic diseases across the globe. The market is expected to grow at a CAGR of 15.6% during the forecast period of 2024-2032, with the values likely to rise from USD 44 billion in 2024 to USD 140.1 billion by 2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Global Genomics Market Overview
Genomics attempts to understand the genetic makeup of an organism and the downstream biological products. This branch of biology has emerged as the most impactful industry trend to treat and prevent diseases. The market demand is driven by multiple factors such as the increased demand for personalized medicine, gene therapy, and the prevalence of chronic diseases like cancer. A study published in Nature Medicine in January 2024 revealed that integrating clinical data with whole genome sequence data can pave the way for precision oncology. Consequently, it would help doctors provide customized treatment plans to patients suffering from cancer, leading to better patient outcomes.
The robust research activities have resulted in the development of a genomic data pool. This data can be utilized by physicians and biologists to find the genetic predisposition to certain diseases. It is expected that the clinical implementation of this genetic data pool will fuel the genomics market growth along with the evolution of a healthcare system that is more tailored to the patient’s needs.
Growth of Genome Editing-Based Therapeutics
The clinical application of genomics can improve the diagnostics system as well as provide personalized treatment options. The recent technological advancements in treatments, employing genomic editing holds the potential to improve the lives of many individuals. In January 2023, CAR-T cell therapy, which works by using genetically modified T cells to identify and destroy specific cancer cells, cured a 13-year-old patient suffering from leukaemia.
The surge in approvals by the regularity authorities has further amplified the genomics market share. In November 2023, the UK Medicines and Health Regulatory Authority (MHRA) approved a CRISPR-based gene therapy known as Casgevy or Exa-cel. This genome-edited cellular therapy utilizes the CRISPR/Cas9 system to produce healthy red blood cells in people with beta-thalassemia and sickle cell disease.
Increased Research Breakthroughs in Genomics
The growing research and clinical trials in the field of genomics, aided by increased funding and technological advancements have led to major research breakthroughs. In August 2023, a research article published in Nature revealed that scientists completed the sequencing of the human Y chromosome. It led to an addition of 30 million new bases in the human genome reference by end-to-end sequencing. The new research is poised to facilitate a better understanding of variation and associated diseases, offering improved therapeutic solutions to critical ailments.
Strategic Investments to Meet Genomics Market Demand
The rising investments by biotechnology firms to accelerate genomic research is expected to reflect significant implications in reshaping the market. In February 2023, Accenture Ventures made a strategic investment in Ocean Genomics, a technology and AI company based in the United States to assist biopharma companies by creating computational platforms. The investment is expected to expedite the development of personalized medicines and artificial intelligence driven drug discovery. The incorporation of technological and scientific advancements in the healthcare system is anticipated to result in improved therapeutics and diagnostics fuelling the market growth.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Global Genomics Market Segmentation
Market Breakup by Deliverables
- Product
- Software and Services
Market Breakup by Technology
- Sequencing
- Microarray
- Polymerase Chain Reaction (PCR)
- Nucleic Acid Extraction
- Purification
- Other
Market Breakup by Process
- Library Preparation
- Data Analysis
- Others
Market Breakup by Application
- Epigenomics
- Functional
- Biomarker Discovery
- Pathway Analysis
- Diagnostics
- Drug Discovery
- Development
- Precision Medicine
- Agriculture
- Animal Research
- Others
Market Breakup by End Users
- Government and Academic Institutes
- Clinical Research
- Healthcare Facilities
- Biotechnology and Pharmaceutical Companies
- Others
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Global Genomics Market Regional Analysis
In North America, the robust healthcare system and increased funding for genomic projects are pushing the market growth. The prevalence of health issues in the region such as cancer, fuels the demand for genomic research in diagnostics and personalized medicine further. As a result, several pharmaceutical companies are collaborating or forming strategic alliances to deliver improved products and services to patients.
Europe holds a significant genomics market share which can be attributed to the existence of major research institutes and healthcare companies that play a pivotal role in increasing the market size.
The growing approvals of gene therapy treatments by health authorities and the evolving preference of patients for minimally invasive treatment procedures have further aided the market growth. In January 2024, Qiagen , a multinational provider of molecular testing solutions based in Germany, received the United States Food and Drug Administration (FDA) approval for NeuMoDx CT/NG Assay employing integrated PCR-based clinical molecular testing system, NeuMoDx 96 and 288 Molecular Systems. This assay utilizing fully automated analysers is designed to provide a rapid and precise diagnosis of sexually transmitted infection (STI).
Global Genomics Market: Competitor Landscape
In January 2024, Veracyte, a global diagnostics company headquartered in the United States, acquired C2i Genomics, a biotechnology company based in Israel known for its minimal residual disease (MRD) tests in a USD 95 million deal. This acquisition aims to employ AI-assisted whole-genome MRD tests to expand the cancer diagnostics range. Thus, the boost in genomic research is supported by major investments in acquisitions, mergers, and expansions by the top biotechnology firms. Consequently, the genomics market value is expected to witness a surge in the forecast period.
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Eppendorf SE
- Eurofins Scientific
- F. Hoffmann-La Roche Ltd
- GE Healthcare
- Freenome Holdings, Inc.
- Myriad Genetics
- Oxford Nanopore Technologies
- PacBio
- QIAGEN
- Thermo Fisher Scientific
- 23andMe
- FOUNDATION MEDICINE
- IntegraGen
- Genome Diagnostics Pvt. Ltd
- Cytiva
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Deliverables |
|
| Breakup by Technology |
|
| Breakup by Process |
|
| Breakup by Application |
|
| Breakup by End Users |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Genomics Market Overview
3.1 Global Genomics Historical Value (2017-2023)
3.2 Global Genomics Forecast Value (2024-2032)
4 Global Genomics Market Landscape
4.1 Global Genomics Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Genomics Product Landscape
4.2.1 Analysis by Technology
4.2.2 Analysis by Application
5 Global Genomics Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
6 Global Genomics Market Segmentation (2017-2032)
6.1 Global Genomics Market (2017-2032) by Deliverables
6.1.1 Market Overview
6.1.2 Product
6.1.3 Software and Services
6.2 Global Genomics Market (2017-2032) by Technology
6.2.1 Market Overview
6.2.2 Sequencing
6.2.3 Microarray
6.2.4 Polymerase Chain Reaction (PCR)
6.2.5 Nucleic Acid Extraction
6.2.6 Purification
6.2.7 Others
6.3 Global Genomics Market (2017-2032) by Process
6.3.1 Market Overview
6.3.2 Library Preparation
6.3.3 Data Analysis
6.3.4 Others
6.4 Global Genomics Market (2017-2032) by Application
6.4.1 Market Overview
6.4.2 Epigenomics
6.4.3 Functional
6.4.4 Biomarker Discovery
6.4.5 Pathway Analysis
6.4.6 Diagnostics
6.4.7 Drug Discovery
6.4.8 Development
6.4.9 Precision Medicine
6.4.10 Agriculture
6.4.11 Animal Research
6.4.12 Others
6.5 Global Genomics Market (2017-2032) by End Users
6.5.1 Market Overview
6.5.2 Government and Academic Institutes
6.5.3 Clinical Research
6.5.4 Healthcare Facilities
6.5.5 Biotechnology and Pharmaceutical Companies
6.5.6 Others
6.6 Global Genomics Market (2017-2032) by Region
6.6.1 Market Overview
6.6.2 North America
6.6.3 Europe
6.6.4 Asia Pacific
6.6.5 Latin America
6.6.6 Middle East and Africa
7 North America Genomics Market (2017-2032)
7.1 North America Genomics Market (2017-2032) by Deliverables
7.1.1 Market Overview
7.1.2 Product
7.1.3 Software and Services
7.2 North America Genomics Market (2017-2032) by Technology
7.2.1 Market Overview
7.2.2 Sequencing
7.2.3 Microarray
7.2.4 Polymerase Chain Reaction (PCR)
7.2.5 Nucleic Acid Extraction
7.2.6 Purification
7.2.7 Others
7.3 North America Genomics Market (2017-2032) by Country
7.3.1 United States of America
7.3.2 Canada
8 Europe Genomics Market (2017-2032)
8.1 Europe Genomics Market (2017-2032) by Deliverables
8.1.1 Market Overview
8.1.2 Product
8.1.3 Software and Services
8.2 Europe Genomics Market (2017-2032) by Technology
8.2.1 Market Overview
8.2.2 Sequencing
8.2.3 Microarray
8.2.4 Polymerase Chain Reaction (PCR)
8.2.5 Nucleic Acid Extraction
8.2.6 Purification
8.2.7 Others
8.3 Europe Genomics Market (2017-2032) by Country
8.3.1 United Kingdom
8.3.2 Germany
8.3.3 France
8.3.4 Italy
8.3.5 Others
9 Asia Pacific Genomics Market (2017-2032)
9.1 Asia Pacific Genomics Market (2017-2032) by Deliverables
9.1.1 Market Overview
9.1.2 Product
9.1.3 Software and Services
9.2 Asia Pacific Genomics Market (2017-2032) by Technology
9.2.1 Market Overview
9.2.2 Sequencing
9.2.3 Microarray
9.2.4 Polymerase Chain Reaction (PCR)
9.2.5 Nucleic Acid Extraction
9.2.6 Purification
9.2.7 Others
9.3 Asia Pacific Genomics Market (2017-2032) by Country
9.3.1 China
9.3.2 Japan
9.3.3 India
9.3.4 ASEAN
9.3.5 Australia
9.3.6 Others
10 Latin America Genomics Market (2017-2032)
10.1 Latin America Genomics Market (2017-2032) by Deliverables
10.1.1 Market Overview
10.1.2 Product
10.1.3 Software and Services
10.2 Latin America Genomics Market (2017-2032) by Technology
10.2.1 Market Overview
10.2.2 Sequencing
10.2.3 Microarray
10.2.4 Polymerase Chain Reaction (PCR)
10.2.5 Nucleic Acid Extraction
10.2.6 Purification
10.2.7 Others
10.3 Latin America Genomics Market (2017-2032) by Country
10.3.1 Brazil
10.3.2 Argentina
10.3.3 Mexico
10.3.4 Others
11 Middle East and Africa Genomics Market (2017-2032)
11.1 Middle East and Africa Genomics Market (2017-2032) by Deliverables
11.1.1 Market Overview
11.1.2 Product
11.1.3 Software and Services
11.2 Middle East and Africa Genomics Market (2017-2032) by Technology
11.2.1 Market Overview
11.2.2 Sequencing
11.2.3 Microarray
11.2.4 Polymerase Chain Reaction (PCR)
11.2.5 Nucleic Acid Extraction
11.2.6 Purification
11.2.7 Others
11.3 Middle East and Africa Genomics Market (2017-2032) by Country
11.3.1 Saudi Arabia
11.3.2 United Arab Emirates
11.3.3 Nigeria
11.3.4 South Africa
11.3.5 Others
12 Regulatory Framework
12.1 Regulatory Overview
12.1.1 US FDA
12.1.2 EU EMA
12.1.3 INDIA CDSCO
12.1.4 JAPAN PMDA
12.1.5 Others
13 Patent Analysis
13.1 Analysis by Type of Patent
13.2 Analysis by Publication Year
13.3 Analysis by Issuing Authority
13.4 Analysis by Patent Age
13.5 Analysis by CPC Analysis
13.6 Analysis by Patent Valuation
13.7 Analysis by Key Players
14 Grants Analysis
14.1 Analysis by Year
14.2 Analysis by Amount Awarded
14.3 Analysis by Issuing Authority
14.4 Analysis by Grant Application
14.5 Analysis by Funding Institute
14.6 Analysis by NIH Departments
14.7 Analysis by Recipient Organization
15 Clinical Trials Analysis
15.1 Analysis by Trial Registration Year
15.2 Analysis by Trial Status
15.3 Analysis by Trial Phase
15.4 Analysis by Therapeutic Area
15.5 Analysis by Geography
16 Funding Analysis by Funding Instances
16.1 Analysis by Type of Funding
16.2 Analysis by Funding Amount
16.3 Analysis by Leading Players
16.4 Analysis by Leading Investors
16.5 Analysis by Geography
17 Partnership and Collaborations Analysis
17.1 Analysis by Partnership Instances
17.2 Analysis by Type of Partnership
17.3 Analysis by Leading Players
17.4 Analysis by Geography
18 Supplier Landscape
18.1 Eppendorf SE
18.1.1 Financial Analysis
18.1.2 Product Portfolio
18.1.3 Demographic Reach and Achievements
18.1.4 Mergers and Acquisitions
18.1.5 Certifications
18.2 Eurofins Scientific
18.2.1 Financial Analysis
18.2.2 Product Portfolio
18.2.3 Demographic Reach and Achievements
18.2.4 Mergers and Acquisitions
18.2.5 Certifications
18.3 F. Hoffmann-La Roche Ltd
18.3.1 Financial Analysis
18.3.2 Product Portfolio
18.3.3 Demographic Reach and Achievements
18.3.4 Mergers and Acquisitions
18.3.5 Certifications
18.4 GE Healthcare
18.4.1 Financial Analysis
18.4.2 Product Portfolio
18.4.3 Demographic Reach and Achievements
18.4.4 Mergers and Acquisitions
18.4.5 Certifications
18.5 Freenome Holdings, Inc.
18.5.1 Financial Analysis
18.5.2 Product Portfolio
18.5.3 Demographic Reach and Achievements
18.5.4 Mergers and Acquisitions
18.5.5 Certifications
18.6 Myriad Genetics
18.6.1 Financial Analysis
18.6.2 Product Portfolio
18.6.3 Demographic Reach and Achievements
18.6.4 Mergers and Acquisitions
18.6.5 Certifications
18.7 Oxford Nanopore Technologies
18.7.1 Financial Analysis
18.7.2 Product Portfolio
18.7.3 Demographic Reach and Achievements
18.7.4 Mergers and Acquisitions
18.8 PacBio
18.8.1 Financial Analysis
18.8.2 Product Portfolio
18.8.3 Demographic Reach and Achievements
18.8.4 Mergers and Acquisitions
18.8.5 Certifications
18.9 QIAGEN
18.9.1 Financial Analysis
18.9.2 Product Portfolio
18.9.3 Demographic Reach and Achievements
18.9.4 Mergers and Acquisitions
18.9.5 Certifications
18.10 Thermo Fisher Scientific
18.10.1 Financial Analysis
18.10.2 Product Portfolio
18.10.3 Demographic Reach and Achievements
18.10.4 Mergers and Acquisitions
18.10.5 Certifications
18.11 23andMe
18.11.1 Financial Analysis
18.11.2 Product Portfolio
18.11.3 Demographic Reach and Achievements
18.11.4 Mergers and Acquisitions
18.11.5 Certifications
18.12 FOUNDATION MEDICIN
18.12.1 Financial Analysis
18.12.2 Product Portfolio
18.12.3 Demographic Reach and Achievements
18.12.4 Mergers and Acquisitions
18.12.5 Certifications
18.13 IntegraGen
18.13.1 Financial Analysis
18.13.2 Product Portfolio
18.13.3 Demographic Reach and Achievements
18.13.4 Mergers and Acquisitions
18.13.5 Certifications
18.14 Genome Diagnostics Pvt. Ltd
18.14.1 Financial Analysis
18.14.2 Product Portfolio
18.14.3 Demographic Reach and Achievements
18.14.4 Mergers and Acquisitions
18.14.5 Certifications
18.15 Cytiva
18.15.1 Financial Analysis
18.15.2 Product Portfolio
18.15.3 Demographic Reach and Achievements
18.15.4 Mergers and Acquisitions
18.15.5 Certifications
List not exhaustive
19 Global Genomics Market- Distribution Model (Additional Insight)
19.1 Overview
19.2 Potential Distributors
19.3 Key Parameters for Distribution Partner Assessment
20 Key Opinion Leaders (KOL) Insights (Additional Insight)
21 Company Competitiveness Analysis (Additional Insight)
21.1 Very Small Companies
21.2 Small Companies
21.3 Mid-Sized Companies
21.4 Large Companies
21.5 Very Large Companies
22 Payment Methods (Additional Insight)
22.1 Government Funded
22.2 Private Insurance
22.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
Key Questions Answered in the Report
The market attained a value of about USD 38.1 billion in 2023 driven by increased funding for genomic projects and the prevalence of chronic diseases across the globe.
The market is anticipated to grow at a CAGR of 15.6% during the forecast period of 2024-2032, likely to reach a market value of USD 140.1 billion by 2032.
The market demand is driven by the increasing prevalence of chronic diseases and the surge in funding and investments in research and development activities in the field of genomics.
The development in minimally invasive cancer screening-based research and growing clinical trials are some of the key trends in the genomics market. In January 2024, Veracyte, a global diagnostics company acquired an Israel-based biotechnology company, C2i Genomics, to expand its cancer diagnostics range.
Product, software and services are major deliverables.
Based on the technology type, the market is divided into sequencing, microarray, polymerase chain reaction (PCR), nucleic acid extraction, purification, and others.
It includes library preparation, and data analysis among others.
Common application areas include epigenomics, functional, biomarker discovery, pathway analysis, diagnostics, drug discovery and development, precision medicine, agriculture, animal research and others.
The various end users include government and academic institutes, clinical research centers, healthcare facilities, pharmaceutical and biotechnology companies, among others.
The major regions of the market include North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa.
Key players involved in the market are Eppendorf SE, Eurofins Scientific, F. Hoffmann-La, Roche Ltd, GE Healthcare, Freenome Holdings, Inc., Myriad Genetics, Oxford Nanopore Technologies, PacBio, QIAGEN, Thermo Fisher Scientific, 23andMe, FOUNDATION MEDICINE, IntegraGen, Genome Diagnostics Pvt. Ltd and Cytiva.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2969
$2699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5499
$4999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 6599
$5999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 7699
$6999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER